title: Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers.
abstract: Efficacies, toxicities, and resistance mechanisms of chemotherapy drugs, such as oxaliplatin and 5-fluorouracil (5-FU), vary widely among various categories and subcategories of colon cancers. By understanding the differences in the drug efficacy and resistance at the level of protein-protein networks, we identified the correlation between the drug activity of oxaliplatin/5-FU and gene variations from the US National Cancer Institute-60 human cancer cell lines. The activity of either of these drugs is correlated with specific amino acid variant(s) of KRAS and other genes from the signaling pathways of colon cancer progression. We also discovered that the activity of a non-DNA-binding novel platinum drug, phosphaplatin, is comparable with oxaliplatin and 5-FU when it was tested against colon cancer cell lines. Our strategy that combines the knowledge from pharmacogenomics across cell lines with the molecular information from specific cancer cells is beneficial for predicting the outcome of a possible combination therapy for personalized treatment.
authors.affiliation: Department of Biology & Biochemistry, University of Houston, Houston, TX, USA.; Department of Physics, University of Houston, Houston, TX, USA.; Center for Theoretical Biological Physics, Rice University, Houston, TX, USA.
authors.forename: Swarnendu
authors.initials: S
authors.lastname: Tripathi
authors.affiliation: Department of Biology & Biochemistry, University of Houston, Houston, TX, USA.
authors.forename: Louiza
authors.initials: L
authors.lastname: Belkacemi
authors.affiliation: Department of Physics, University of Houston, Houston, TX, USA.; Center for Theoretical Biological Physics, Rice University, Houston, TX, USA.
authors.forename: Margaret S
authors.initials: MS
authors.lastname: Cheung
authors.affiliation: Department of Biology & Biochemistry, University of Houston, Houston, TX, USA.
authors.forename: Rathindra N
authors.initials: RN
authors.lastname: Bose
keywords: KRAS; chemotherapy; colon cancer; fluorouracil; oxaliplatin; platinum drugs
references.citation: J Natl Compr Canc Netw. 2011 Nov;9 Suppl 5:S1-32; quiz S33
references.pmid: 22138009
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7
references.pmid: 11097226
references.citation: Gastroenterology. 2011 Sep;141(3):1003-1013.e1-10
references.pmid: 21699772
references.citation: Nature. 2009 Apr 9;458(7239):719-24
references.pmid: 19360079
references.citation: Int J Nanomedicine. 2014 Jul 16;9:3403-11
references.pmid: 25075187
references.citation: J Natl Cancer Inst. 2014 Feb;106(2):djt373
references.pmid: 24491301
references.citation: Nucleic Acids Res. 2000 Jan 1;28(1):27-30
references.pmid: 10592173
references.citation: Int J Cancer. 2010 Jul 1;127(1):195-206
references.pmid: 19904749
references.citation: Oncogene. 2003 Jul 17;22(29):4581-5
references.pmid: 12881715
references.citation: Clin Cancer Res. 2014 Sep 1;20(17):4419-21
references.pmid: 24916693
references.citation: Nature. 2004 Nov 18;432(7015):294-7
references.pmid: 15549090
references.citation: Nat Rev Cancer. 2006 Oct;6(10):813-23
references.pmid: 16990858
references.citation: Clin Colon Rectal Surg. 2009 Nov;22(4):191-7
references.pmid: 21037809
references.citation: Curr Drug Discov Technol. 2011 Jun;8(2):119-25
references.pmid: 21513489
references.citation: Nat Rev Cancer. 2007 Apr;7(4):295-308
references.pmid: 17384584
references.citation: Gastroenterology. 2008 Oct;135(4):1079-99
references.pmid: 18773902
references.citation: Oncotarget. 2014 Sep 15;5(17):7285-302
references.pmid: 25277176
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18314-9
references.pmid: 19020081
references.citation: Pharmacol Rev. 2011 Jun;63(2):437-59
references.pmid: 21436344
references.citation: Oncologist. 2007 Dec;12(12):1443-55
references.pmid: 18165622
references.citation: Transl Oncol. 2013 Jun 01;6(3):363-9
references.pmid: 23730417
references.citation: J Natl Cancer Inst. 1998 May 6;90(9):675-84
references.pmid: 9586664
references.citation: Rev Med Virol. 2015 Mar;25 Suppl 1:24-53
references.pmid: 25752815
references.citation: Nat Rev Clin Oncol. 2010 Jul;7(7):401-14
references.pmid: 20551945
references.citation: Gut. 2005 Sep;54(9):1283-6
references.pmid: 15843421
references.citation: Patholog Res Int. 2011 Feb 14;2011:932932
references.pmid: 21403829
references.citation: Br J Cancer. 2002 Apr 8;86(7):1162-8
references.pmid: 11953866
references.citation: Virology. 2013 Sep 1;443(2):294-305
references.pmid: 23791019
references.citation: Nat Rev Cancer. 2013 Oct;13(10):714-26
references.pmid: 24060863
references.citation: Cell. 1990 Jun 1;61(5):759-67
references.pmid: 2188735
references.citation: J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
references.pmid: 2041050
references.citation: Gut. 1997 May;40(5):660-3
references.pmid: 9203947
references.citation: Cancer Res. 1989 Sep 1;49(17):4682-9
references.pmid: 2547513
references.citation: Cell. 1996 Oct 18;87(2):159-70
references.pmid: 8861899
references.citation: Br J Cancer. 2014 Feb 18;110(4):946-57
references.pmid: 24384683
references.citation: J Gastrointest Oncol. 2011 Mar;2(1):27-33
references.pmid: 22811824
references.citation: Cancer Biol Ther. 2012 Jan 1;13(1):34-42
references.pmid: 22336586
references.citation: Int J Mol Sci. 2015 Jan 22;16(2):2472-96
references.pmid: 25622259
references.citation: Nat Rev Cancer. 2009 Jul;9(7):489-99
references.pmid: 19536109
references.citation: Br J Cancer. 2001 Sep 1;85(5):692-6
references.pmid: 11531254
references.citation: Int J Mol Sci. 2013 Aug 07;14(8):16365-85
references.pmid: 23965959
references.citation: Pathol Res Pract. 2009;205(12 ):858-62
references.pmid: 19679400
references.citation: Tumour Biol. 2014 Jul;35(7):6195-206
references.pmid: 25051912
references.citation: Pharmacology. 2008;81(4):275-300
references.pmid: 18259091
references.citation: Nat Rev Gastroenterol Hepatol. 2011 Oct 18;8(12):686-700
references.pmid: 22009203
references.citation: Nature. 2013 Oct 17;502(7471):333-9
references.pmid: 24132290
references.citation: Nat Rev Clin Oncol. 2010 May;7(5):251-65
references.pmid: 20351699
references.citation: Nat Med. 2013 Nov;19(11):1389-400
references.pmid: 24202392
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2059-69
references.pmid: 12775730
references.citation: Nature. 2012 Mar 28;483(7391):603-7
references.pmid: 22460905
references.citation: PLoS One. 2014 Jul 17;9(7):e101670
references.pmid: 25032700
references.citation: Science. 2013 Mar 29;339(6127):1546-58
references.pmid: 23539594
references.citation: Cancer Res. 2013 Jul 15;73(14):4372-82
references.pmid: 23856246
references.citation: Mol Cancer. 2014 May 31;13:135
references.pmid: 24885062
references.citation: Nat Chem Biol. 2008 Nov;4(11):682-90
references.pmid: 18936753
references.citation: J Med Chem. 2015 Nov 12;58(21):8387-401
references.pmid: 26455832
references.citation: PLoS One. 2013 Oct 23;8(10 ):e78355
references.pmid: 24194922
references.citation: Eur J Cancer. 1997 Feb;33(2):214-9
references.pmid: 9135491
references.citation: Arzneimittelforschung. 2008;58(6):261-4
references.pmid: 18677966
references.citation: Sci Signal. 2015 Sep 01;8(392):pe1
references.pmid: 26329580
references.citation: Nat Med. 2004 Aug;10 (8):789-99
references.pmid: 15286780
references.citation: Cancer Res. 2012 Jul 15;72(14):3499-511
references.pmid: 22802077